1. Home
  2. RSLS vs CDT Comparison

RSLS vs CDT Comparison

Compare RSLS & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RSLS
  • CDT
  • Stock Information
  • Founded
  • RSLS 2002
  • CDT 2019
  • Country
  • RSLS United States
  • CDT United States
  • Employees
  • RSLS N/A
  • CDT N/A
  • Industry
  • RSLS Medical/Dental Instruments
  • CDT Biotechnology: Pharmaceutical Preparations
  • Sector
  • RSLS Health Care
  • CDT Health Care
  • Exchange
  • RSLS Nasdaq
  • CDT Nasdaq
  • Market Cap
  • RSLS 4.5M
  • CDT 5.3M
  • IPO Year
  • RSLS 2007
  • CDT N/A
  • Fundamental
  • Price
  • RSLS $6.66
  • CDT $0.40
  • Analyst Decision
  • RSLS Hold
  • CDT
  • Analyst Count
  • RSLS 1
  • CDT 0
  • Target Price
  • RSLS N/A
  • CDT N/A
  • AVG Volume (30 Days)
  • RSLS 17.0M
  • CDT 3.1M
  • Earning Date
  • RSLS 05-19-2025
  • CDT 05-20-2025
  • Dividend Yield
  • RSLS N/A
  • CDT N/A
  • EPS Growth
  • RSLS N/A
  • CDT N/A
  • EPS
  • RSLS N/A
  • CDT N/A
  • Revenue
  • RSLS $8,006,000.00
  • CDT N/A
  • Revenue This Year
  • RSLS $52.80
  • CDT N/A
  • Revenue Next Year
  • RSLS N/A
  • CDT N/A
  • P/E Ratio
  • RSLS N/A
  • CDT N/A
  • Revenue Growth
  • RSLS N/A
  • CDT N/A
  • 52 Week Low
  • RSLS $0.30
  • CDT $0.51
  • 52 Week High
  • RSLS $29.00
  • CDT $350.00
  • Technical
  • Relative Strength Index (RSI)
  • RSLS 38.68
  • CDT 31.06
  • Support Level
  • RSLS $9.75
  • CDT $0.37
  • Resistance Level
  • RSLS $11.65
  • CDT $0.57
  • Average True Range (ATR)
  • RSLS 1.23
  • CDT 0.05
  • MACD
  • RSLS 0.52
  • CDT 0.01
  • Stochastic Oscillator
  • RSLS 13.19
  • CDT 13.89

About RSLS ReShape Lifesciences Inc.

Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus. Geographically, the company operates in the United States, Australia, Europe, and the Rest of world, and the majority of its revenue is generated from the United States.

About CDT Conduit Pharmaceuticals Inc.

Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Share on Social Networks: